In 2011 this blog was listed as one of the top 10 blog in pharma technical information it is popular amongst the pharmacists and pharma industry professionals. We have published very important and very useful information for pharma industry professionals.

Friday, April 28, 2023

Sterile drug manufacturing facility audit considerations

Sterile drug products / Injectable dosage form manufacturing facility audit.

The questionnaire is intended to cover the manufacture of all sterile drug products, including sterile bulk drugs, ophthalmic and ophthalmic dosage forms, Small Volume Parenteral (SVP) products, Large Volume Parenteral ( LVP) products, and any other drug products required to be sterile.

This article will help you for conducting inspections of manufacturers of sterile bulk and finished dosage form drug products to determine compliance with the Food, Drug, and Cosmetic Act and
the Good Manufacturing Practice Regulations (GMPs), Title 21, CFR Parts 210 and 211
Inspections of sterile product manufacturing firms are performed as either Full Inspections or Abbreviated inspections. In the Abbreviated Inspection, coverage are directed to key
points in the major systems affecting the production of the sterile drug product. If the information collected indicates that the firm's practices are in compliance with CGMPs, the
inspection may be concluded at this point. When questionable practices are observed in areas outside of the systems delineated under this option, the investigator is urged to expand the inspection to cover these areas to his/her satisfaction.

The full Inspection option involves an in depth inspection of key manufacturing systems and processes and their validation in order to maintain surveillance over the firm's activities.

Consider using a team approach in conducting these inspections, utilizing investigators familiar with these processes, and chemists, microbiologists, and engineers, as appropriate.

Investigators or team members should be well qualified in sterile product production experience and preferably have completed formal training courses in parenteral drug manufacture, sterilization methods, procedures and equipment. Microbiologists involved should have experience in sterility/pyrogen testing and some experience in sterile product inspections

Determine if changes have occurred by comparing current operations against the EIR for the previous full inspection. The following type of changes are typical of those that would warrant the Full Inspection Option

1.New potential for cross-contamination arising through change in process or product line.

2. Use of new technology requiring new expertise, significantly new equipment or new facilities

3.Review the firm's complaint file, annual product reviews, etc. and determine if the pattern of complaints as well as the firm's records of internal rejection or reworking of batches warrant expanding the inspection to the pu11 Inspection Option to look for weaknesses in the firm's processes, systems or controls

4. If no significant changes have occurred and no violative conditions are observed, the Abbreviated Inspection Option are considered adequate.

5. If significant changes have occurred, or if violative or potentially violative conditions are noted, the inspection are expanded to the Full Inspection Option to provide appropriate coverage.

Inspection is performed for the firm's manufacturing facility including a review of a representative number of Master and Batch Production Records (minimum of 5 batches) on products manufactured by the firm. Products that appear in the firm's inspectional history of previous problems should be included. A brief inspection of the laboratory should include a spot check of a limited number of test records (at least 10) to assure that batches are being subjected to adequate testing for conformance to specifications

Special note should be taken of the firm's packaging and labeling controls. Any observation of inadequate controls will indicate that a Full inspectional Option should be performed. If the following type of procedures are encountered, in-depth inspectional coverage should be given
to the firm's Labeling systems:

The use of labels which are similar in size, shape, and color for different products.
The use of cut labels which are similar in appearance without some type of 100 percent electronic verification system for the finished product.
If the use of gang printing of cut labels is not minimized as required by current regulations.
If the firm has had more than one mislabeling recall in the past two years.
If the firm fills product into unlabeled containers which are later labeled under multiple private labels.
The inspection will focus on the major systems that impact on the safety and effectiveness of all sterile products manufactured by the firm:

Sterilization procedures applied to the drug product; components; container/closures; product contact equipment and surfaces
1.water systems  (preparation of water for injection)
2.air handling
3.environmental monitoring
4.handling of incoming components
5.packaging and labeling
7.lyophilization (where applicable)

It is suggested that one drug product be selected and followed throughout; if the firm utilizes more than one type of drug product sterilization process, one drug product representing each
type of sterilization process should be selected.
When selecting a drug product for review, drugs that are listed in the firm's complaint files should be considered.

Drug product information collected is as follows:
A. Name of Selected Drug
B. Dosage Size
C. Strength
D. itch sizes
E. Number of batches per year

What type of sterile drug products are manufactured by this firm:
F. Small Volume Parantral
G. Large Volume Parantral
H. Ophthalmics
I. Sterile Otics
J. Sterile Bulk
K. Other (identify)
Indicate whether any of these products are lyophilized.

The inspections are done on separate sections for each unique drug product and sterilization process investigated.


Documentary or physical samples are collected, including in-process samples where possible, to document any suspected adulteration and misbranding problems encountered during the inspection.

If microbiological contamination is suspected, document where possible the conditions which could contribute microbiological contamination to the product both by collecting records and
physical samples taken aseptically at points where such contamination might occur, such as from the water for injection WFI system. Products found positive on initial sterility testing should also be
considered for sampling. Physical samples should not be collected if the estimated level
of microbial contamination is low.
Collect samples for particulate matter contamination where inspectional observations indicate poor manufacturing practices have possibly contributed to the introduction of particulate
matter into these products or where finished product controls are inadequate to assure rejection of such units.

Sample Size
(determining sample sizes for endotoxin and sterility evaluation)


Routine chemical analyses
Sterility Testing:
Other microbiological examinations
Salmonella Serotyping
Chemical cross-contamination analyses by mass spectrometry (MS)
Particulate Matter in Injectables

1. Samples are to be examined for compliance with applicable specifications. Check analyses will be by the official method, or when no official method exists, by other validated procedures.

2. The presence of cross-contamination must be confirmed by a second method. Spectroscopic methods, such as MS, NMR, UVvisible, or infrared are preferred. However, a second
chromatographic method may be employed, provided the chromatographic mechanisms are different (e.g., ion-pairing vs. conventional reverse phase HPLC).

3. Sterility testing methods should be based on USP and the Sterility Analytical Manual Other microbiological examinations should be based on appropriate sections of USP

Part 1 Inspection and facility audit questionnaire for sterile dosage form

Part 2 Sterile drug manufacturing facility audit questionnaire

Part 3 Sterile drug / Injectable dosage form manufacturing facility inspection questionnaire

Media fill Failed ?

Media fill Test .Assurance of Sterility of preantral dosage form , Injectables

What is Media Fill

What is a High-Efficiency Particulate Air Filter (HEPA filter)

What is a Laminar Air Flow Cabinet.

 Clean Room Classification

Pharma sales Jobs find Job in pharma company

Revalidations in pharmaceutical manufacturing

Requirements of Building and Facilities for Sterile Dosage form , Injectables

1 comment:

Anonymous said...

This blog is one of great resource for pharma industry professionals i am following this blog since three years and found that this blog has emerged as one of popular among pharmacists and industry

What is 21 CFR Part 11, US FDA guidelines requirements of FDA compliance and CFR 21 Part 11.

What is a Site Master file of a pharmaceutical company

What is Generic Drug

What is Reference Listed Drug  ? ( RLD )

What is Pharmaceutical Equivalents

What is Pharmaceutical Alternatives

What is Therapeutic Equivalents

What are Post Market studies

Why a drug is bound to protein, What is protein binding?  What is drug absorption , distribution ?

Do Physical properties contribute to drug activity.

What is drug receptor , How a drug resistance occurs

Mechanism of drug resistance

What is drug interaction

Drug interaction, and its examples

What is first pass metabolism of a drug

What is What is 510(k) Clearances ?

What is 510(k) Clearances,

Premarket Notification for medical devices - PMN or 510(k)

What is a drug interaction

Examples of drug interactions

Antibiotic Definition and classification

Antibiotic Resistance and Antibiotic resistance mechanism

Antioxidants food supplements

Vitamin D Details on FDA cautions on accurate dosage of Vitamin D

What is an antibody? what is monoclonal and polyclonal antibodies?

Terminologies In vaccine Production

Multi stage testing of Virus vaccine production

Testing of vaccines at different stages of production


Enzyme linked immunosorbent assay ELISA

Raido Immuno assay

Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.

Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in

pharmaceutical industry

Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing

Requirements of documents for validation of sterilisation process

How to investigate OOS out of specification results

Determination of Phenol coefficient of a disinfectant

Sterility testing

Clean Room Classification

Time limitations in sterile pharmaceuticals processing

Aspects of validation of manufacturing process in sterile pharmaceuticals

Clinical Trials

Requirements of US FDA Inspections of Clinical Investigators of Clinical Trials




Controlling Pyrogens in injectable dosage forms

Media fill run process simulation aspects Validation of Aseptic Process and Sterilisation

New Drug Application (NDA) how to make a New Drug Application (NDA) to US FDA

Abbreviated New Drug Application (ANDA) What is ANDA , detailed information about ANDA preparation and submission to US FDA

How to make Investigational New Drug (IND) Application to US FDA

Drug applications submission to us fda Over the counter Drugs OTC drugs


Electronic record in pharmaceutical manufacturing industry

Good manufacturing practice in pharmaceutical industry

Pharmaceutical industry pharmaceutical companies and FDA latest updates